My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.348 -0.012 (-0.88%)

Streaming Delayed Price Updated: 12:47 PM EDT, Oct 14, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	84,052
Open	1.330
Bid (Size)	1.320 (3)
Ask (Size)	1.350 (2)
Prev. Close	1.360
Today's Range	1.300 - 1.350
52wk Range	0.9400 - 1.919
Shares Outstanding	15,641,611
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

NanoViricides, Inc. Has Filed its Annual Report

September 30, 2025

Via ACCESS Newswire

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

September 11, 2025

Via ACCESS Newswire

Performance

YTD	-5.1%	-5.1%
1 Month	-7.0%	-7.0%
3 Month	-15.7%	-15.7%
6 Month	+13.3%	+13.3%
1 Year	-5.7%	-5.7%

More News

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025

September 10, 2025

Via Investor Brand Network

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

September 09, 2025

Via ACCESS Newswire

NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence

August 27, 2025

Via AB Newswire

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

August 18, 2025

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks

July 30, 2025

Via Investor Brand Network

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

July 30, 2025

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387’s Broad Antiviral Potential and Strategic Value for Pandemic Preparedness

July 23, 2025

Via Investor Brand Network

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

July 23, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's After-Market Session

July 22, 2025

Via Benzinga

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study

July 21, 2025

Via Investor Brand Network

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides, Inc. (NYSE American: NNVC) Highlights MPox Drug Progress as WHO Extends Global Health Emergency

July 16, 2025

Via Investor Brand Network

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Finalizes Adaptive Trial Design for MPox Drug NV-387

July 14, 2025

Via Investor Brand Network

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

July 14, 2025

Via ACCESS Newswire

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

July 01, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness

June 18, 2025

Via Investor Brand Network

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

June 18, 2025

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks

June 04, 2025

Via Investor Brand Network

NanoViricides Measles Drug Development Animal Study is Imminent

June 04, 2025

Via ACCESS Newswire

NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention

June 02, 2025

Via AB Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention

May 28, 2025

Via Investor Brand Network

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?

Yes, NanoViricides, Inc. Common Stock is publicly traded.

What exchange does NanoViricides, Inc. Common Stock trade on?

NanoViricides, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for NanoViricides, Inc. Common Stock?

The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange

What is the current price of NanoViricides, Inc. Common Stock?

The current price of NanoViricides, Inc. Common Stock is 1.348

When was NanoViricides, Inc. Common Stock last traded?

The last trade of NanoViricides, Inc. Common Stock was at 10/14/25 12:47 PM ET

What is the market capitalization of NanoViricides, Inc. Common Stock?

The market capitalization of NanoViricides, Inc. Common Stock is 21.08M

How many shares of NanoViricides, Inc. Common Stock are outstanding?

NanoViricides, Inc. Common Stock has 21M shares outstanding.

Recent Quotes

Symbol	Price	Change (%)
GOOG	247.57	+2.93 (1.20%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.